Browse Category

EHA 2023

19 Articles

EHA 2023

The therapeutic revolution for the management of multiple myeloma

June 15, 2023

Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura...

EHA 2023

The phase 1/2 Bruin study

June 14, 2023

Prof. Wojciech Jurczak discussed the data from the phase 1 / 2 Bruin study...

EHA 2023

In the spotlight: Jan Cools, editor-in-chief of HemaSphere

June 13, 2023

MediMix had an interview with Prof. Jan Cools from KU Leuven and...

EHA 2023

The unmet need in patients with multiple myeloma at first relapse

June 12, 2023

Prof. Maria Victoria Mateos, hematologist at the Hospital Universitario De...

EHA 2023

Highlights on infections and SCT complications

June 12, 2023

Dr. Alexander Schauwvlieghe chaired the session on infections and SCT...

EHA 2023

BTK inhibitors as first line treatment in mantle cell lymphoma: a debate

June 11, 2023

Dr. Jeanette Doorduijn, hematologist at the Erasme hospital in Rotterdam...

EHA 2023

Highlights on platelets and inflammation

June 11, 2023

Professor Kimberly Martinod from the Department of Cardiovascular Sciences at...

EHA 2023

Ageing and hematology: how to cope with the silver wave in hematology

June 10, 2023

Prof. em. Dominique Bron provided a comprehensive summary of the EHA...

EHA 2023

Advances in the science and care of persons with bleeding disorders

June 10, 2023

Prof. Cathérine Lambert gives an overview of the session ‘Advances in the...

EHA 2023

Diagnosis and treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

June 10, 2023

Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura...